DNA & Genetics Korro Craters 81% on Data; Patient Death Sours Analysts on IntelliaBy adminNovember 18, 20250 Korro Bio (NASDAQ: KRRO) saw its stock reach its first of two all-time lows, cratering 81% Thursday after reporting disappointing…
DNA & Genetics Patient Dies After Treatment with Intellia CRISPR Therapy in Phase III TrialBy adminNovember 8, 20250 Credit: TopMicrobialStock / Adobe Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase…
DNA & Genetics Intellia Shares Sink as Clinical Hold Follows Safety SetbackBy adminNovember 2, 20250 John Leonard, MD, Intellia Therapeutics president and CEO Addressing analysts in August, Intellia Therapeutics (NASDAQ: NTLA) president and CEO John…
